A New York federal judge dismissed allegations on Monday that Bristol Myers Squibb purposely delayed Breyanzi’s approval to ...
As the potential end of Robert Califf's time as FDA commissioner nears, he and a key deputy are continuing to push forward ...
California Gov. Gavin Newsom vetoed bipartisan legislation on Saturday that would have reformed pharmacy benefit managers in ...
Johnson & Johnson has called off plans to implement a new rebate model for 340B drug price discounts following threats from ...
Pfizer will continue shrinking its ownership in the British consumer health company Haleon, according to an announcement ...
Ge­nom­ic med­i­cines start­up En­so­ma is shut­ter­ing its Copen­hagen site and al­so elim­i­nat­ing “a very small num­ber” ...
Poseida Therapeutics said that 21 of 23 patients (91%) responded to the allogeneic CAR-T therapy it’s developing with Roche ...
Kezar Life Sciences is suspending enrollment and dosing in a lupus trial after four patients died in the mid-stage study of ...
DCVC Bio confirmed it has put together a $400 million third fund, four years after raising $350 million in its sophomore ...
Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...
As other young radiopharmaceutical companies get acquired by drugmakers, Boston-based Aktis Oncology wants to become one of ...
Johnson & Johnson and Legend Biotech's CAR-T cell therapy Carvykti reduced the risk of death by 45% compared to standard of ...